Colin C. Pritchard MD, PhD, presented “Molecular Insights into the Germline for Prostate Cancer Initiation, Progression, and Aggressiveness” for the Grand Rounds in Urology audience in January, 2020.
How to cite: Pritchard, Colin C. “Molecular Insights into the Germline for Prostate Cancer Initiation, Progression, and Aggressiveness” January, 2020. Accessed Feb 2020. https://grandroundsinurology.com/molecular-insights-into-the-germline-for-prostate-cancer-initiation-progression-and-aggressiveness/
Molecular Insights into the Germline for Prostate Cancer Initiation, Progression, and Aggressiveness – Summary:
Colin C. Pritchard, MD, PhD, Director of the Genetics and the Solid Tumors Laboratory at the University of Washington, discusses how germline testing and next-generation sequencing (NGS) of tumors have become important for guiding prostate cancer diagnosis, treatment, and assessment of risk. He details DNA damage response (DDR) genes, including key pathways, potential risk factors, and general characteristics. He also discusses the role of molecular pathologists in testing samples, choosing methodology, and interpreting results.
This educational activity is based on a series of lectures on genetic testing for prostate cancer from the 2019 Philadelphia Prostate Cancer Consensus Conference. Further activities from this conference include:
Germline Predisposition for Prostate Cancer Among African American and Other Minorities: What Do We Know?
Prostate Cancer Screening & Genetic Testing: The NCCN Perspective
Current NCCN Recommendations for Prostate Cancer Genetic Testing
The Expanding World of Germline Testing for Prostate Cancer: Genetic Counseling Perspective
The Expanding World of Germline Testing for Prostate Cancer: A Clinical Trials Perspective
Current Prostate Cancer Genetic Testing Capabilities and Considerations
A Urologist’s Perspective on Germline Testing
Integration of Germline Testing in Prostate Cancer Screening